dc.contributor.author | Tekeli, İbrahim Özan | |
dc.contributor.author | Ateşşahin, Ahmet | |
dc.contributor.author | Sakin, Fatih | |
dc.contributor.author | Aslan, Abdullah | |
dc.contributor.author | Çeribaşı, Songül | |
dc.contributor.author | Yipel, Mustafa | |
dc.date.accessioned | 2022-05-11T14:42:18Z | |
dc.date.available | 2022-05-11T14:42:18Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 0925-4692 | |
dc.identifier.issn | 1568-5608 | |
dc.identifier.uri | https://doi.org/10.1007/s10787-018-0485-x | |
dc.identifier.uri | https://hdl.handle.net/20.500.11776/9327 | |
dc.description.abstract | ObjectiveTo compare the potential protective effects of conventional and colon-targeted lycopene (TLC) and linalool (TLN) on acetic acid (AA)-induced ulcerative colitis (UC) in rats.MethodsConventional and colon-targeted LC (10mg/kg) and LN (200mg/kg) were administered in vivo orally for 7days and sulfasalazine (100mg/kg) was also used as reference drug. Then, 4% AA was administered intrarectally to induce UC. Subsequently, the colon tissues were taken as samples for biochemical and histopathological analysis.ResultsMalondialdehyde (MDA), interleukin 1 (IL-1), IL-6, cyclooxygenase-2 (COX-2) and nuclear factor kappa B (NF-B) levels were decreased (p<0.05) in the targeted groups compared to the AA group, whereas nuclear factor-erythroid 2-related factor 2 (Nrf-2) level was increased (p<0.05). Tumor necrosis factor (TNF-) level was also decreased (p<0.05) and catalase activity (CAT) was increased (p<0.05) in the TLC group compared to the AA group. IL-1 and IL-6 levels were lower in the TLC group compared to the conventional LC and sulfasalazine groups (p<0.05). COX-2 and NF-B levels were lower, while the Nrf-2 level was higher in the targeted groups compared to the conventional groups (p<0.05). Furthermore, COX-2 level was lower and Nrf-2 level was higher in the targeted groups compared to the sulfasalazine group (p<0.05).ConclusionAs expected, sulfasalazine was effective on all parameters analyzed, but the colon-targeted pretreatments were more effective from sulfasalazine on some parameters. Therefore, colon-targeted plant-derived therapies might be alternative approaches to provide protection against UC, which deserves to be investigated further. | en_US |
dc.description.sponsorship | Scientific Research Projects Coordination of Mustafa Kemal University [14025] | en_US |
dc.description.sponsorship | This work was financially supported by Scientific Research Projects Coordination of Mustafa Kemal University (project number: 14025). | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Springer Basel Ag | en_US |
dc.identifier.doi | 10.1007/s10787-018-0485-x | |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Ulcerative colitis | en_US |
dc.subject | Colon targeting | en_US |
dc.subject | Lycopene | en_US |
dc.subject | Linalool | en_US |
dc.subject | Rat | en_US |
dc.subject | Nf-Kappa-B | en_US |
dc.subject | Inflammatory-Bowel-Disease | en_US |
dc.subject | Oxidative Stress | en_US |
dc.subject | 5-Aminosalicylic Acid | en_US |
dc.subject | Colorectal-Cancer | en_US |
dc.subject | Succinyl-Chitosan | en_US |
dc.subject | Cox-2 Expression | en_US |
dc.subject | In-Vivo | en_US |
dc.subject | Activation | en_US |
dc.subject | Delivery | en_US |
dc.title | Protective effects of conventional and colon-targeted lycopene and linalool on ulcerative colitis induced by acetic acid in rats | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Inflammopharmacology | en_US |
dc.department | Fakülteler, Veteriner Fakültesi, Klinik Öncesi Bilimler Bölümü, Farmakoloji ve Toksikoloji Ana Bilim Dalı | en_US |
dc.authorid | 0000-0002-6243-4221 | |
dc.authorid | 0000-0002-6845-2279 | |
dc.authorid | 0000-0002-1004-2146 | |
dc.identifier.volume | 27 | en_US |
dc.identifier.issue | 2 | en_US |
dc.identifier.startpage | 313 | en_US |
dc.identifier.endpage | 322 | en_US |
dc.institutionauthor | Yipel, Mustafa | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.authorscopusid | 57190766109 | |
dc.authorscopusid | 7801309581 | |
dc.authorscopusid | 14037995800 | |
dc.authorscopusid | 27367627900 | |
dc.authorscopusid | 36561114600 | |
dc.authorscopusid | 55897696600 | |
dc.authorwosid | Aslan, Abdullah/C-9523-2016 | |
dc.authorwosid | Tekeli, Ibrahim Ozan/W-3685-2017 | |
dc.identifier.wos | WOS:000465595000010 | en_US |
dc.identifier.scopus | 2-s2.0-85046531925 | en_US |
dc.identifier.pmid | 29736689 | en_US |